Furthermore, 47% (95% CI: 39.6–54.5) of patients with PSC-IBD achieved clinical response post-biologic therapy, with similar response rates for vedolizumab and anti-TNF alpha inhibitors (data not shown). The gene discussed is TNF; the disease is inflammatory bowel disease.